JP2017506264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506264A5 JP2017506264A5 JP2016570201A JP2016570201A JP2017506264A5 JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5 JP 2016570201 A JP2016570201 A JP 2016570201A JP 2016570201 A JP2016570201 A JP 2016570201A JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- composition according
- ctla
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN499DE2014 | 2014-02-21 | ||
| IN499/DEL/2014 | 2014-02-21 | ||
| IN3087/DEL/2014 | 2014-10-29 | ||
| IN3087DE2014 | 2014-10-29 | ||
| PCT/IN2015/000099 WO2015125159A1 (en) | 2014-02-21 | 2015-02-20 | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Division JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506264A JP2017506264A (ja) | 2017-03-02 |
| JP2017506264A5 true JP2017506264A5 (enExample) | 2018-01-18 |
| JP6963385B2 JP6963385B2 (ja) | 2021-11-10 |
Family
ID=53055076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570201A Active JP6963385B2 (ja) | 2014-02-21 | 2015-02-20 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10010587B2 (enExample) |
| EP (2) | EP3834838A1 (enExample) |
| JP (3) | JP6963385B2 (enExample) |
| KR (1) | KR102410090B1 (enExample) |
| CN (1) | CN106132438B (enExample) |
| AU (3) | AU2015220408B2 (enExample) |
| CA (1) | CA2937660A1 (enExample) |
| CY (1) | CY1124226T1 (enExample) |
| DK (1) | DK3134123T3 (enExample) |
| ES (1) | ES2872848T3 (enExample) |
| HR (1) | HRP20210377T1 (enExample) |
| HU (1) | HUE053982T2 (enExample) |
| IL (1) | IL247320B (enExample) |
| LT (1) | LT3134123T (enExample) |
| MX (2) | MX385194B (enExample) |
| PL (1) | PL3134123T3 (enExample) |
| PT (1) | PT3134123T (enExample) |
| RS (1) | RS61661B1 (enExample) |
| SI (1) | SI3134123T1 (enExample) |
| SM (1) | SMT202100191T1 (enExample) |
| WO (1) | WO2015125159A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2655409A4 (en) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 |
| CA2932765A1 (en) | 2013-12-05 | 2015-06-11 | Rfemb Holdings, Llc | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| SMT202100191T1 (it) | 2014-02-21 | 2021-05-07 | Nektar Therapeutics | Agonisti selettivi per il-2rbeta in combinazione con un anticorpo anti.ctla-4 o un anticorpo anti-pd-1 |
| CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
| KR102128856B1 (ko) | 2015-01-30 | 2020-07-02 | 알에프이엠비 홀딩스, 엘엘씨 | 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템 |
| MA42459A (fr) | 2015-07-16 | 2018-05-23 | Bioxcel Therapeutics Inc | Nouvelle approche pour le traitement du cancer par immunomodulation |
| EP3356827B1 (en) | 2015-10-02 | 2023-12-06 | Julius-Maximilians-Universität Würzburg | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| MX2018004296A (es) | 2015-10-08 | 2018-08-01 | Nektar Therapeutics | Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada. |
| KR20180113976A (ko) | 2015-11-20 | 2018-10-17 | 센화 바이오사이언시즈 인코포레이티드 | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 |
| TWI834598B (zh) | 2016-01-15 | 2024-03-11 | 美商Ｒｆｅｍｂ控股有限公司 | 癌症之免疫治療 |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| AU2017312121A1 (en) * | 2016-08-19 | 2019-03-21 | Brooklyn Immunotherapeutics Llc | Uses of PD-1/PD-L1 inhibitors and/or CTLA-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
| WO2018089669A2 (en) * | 2016-11-10 | 2018-05-17 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| CN110167598A (zh) | 2017-01-10 | 2019-08-23 | 尼克塔治疗公司 | Tlr激动剂化合物的多臂聚合物缀合物以及相关的免疫治疗方法 |
| WO2018160877A1 (en) * | 2017-03-01 | 2018-09-07 | Nektar Therapeutics | Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| MA48862A (fr) * | 2017-05-02 | 2020-04-01 | Nektar Therapeutics | Méthode de traitement de tumeur immunothérapeutique |
| AU2018271751B2 (en) * | 2017-05-25 | 2021-04-01 | Institute For Basic Science | Anti-human interleukin-2 antibodies and uses thereof |
| WO2018234862A1 (en) | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
| US12030940B2 (en) | 2017-08-17 | 2024-07-09 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019090330A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20210154277A1 (en) * | 2017-11-07 | 2021-05-27 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| EP3710035A4 (en) * | 2017-11-13 | 2021-12-29 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| RU2020120145A (ru) | 2017-11-21 | 2021-12-22 | Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити | Частичные агонисты интерлейкина-2 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| RU2020130050A (ru) | 2018-02-15 | 2022-03-15 | Сэньхва Байосайенсиз, Инк. | Аналоги хинолонов и их соли, композиции и способ их применения |
| AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| IL277572B2 (en) * | 2018-03-28 | 2024-05-01 | Ascendis Pharma Oncology Div A/S | Il-2 conjugates |
| CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| MX2020012248A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| JP2022509917A (ja) | 2018-11-05 | 2022-01-25 | ファイザー・インク | がんを処置するための組合せ |
| EP3876940A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinations for treating cancer |
| CN113316590B (zh) | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| EP4058471A1 (en) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| EP4087865A2 (en) | 2020-01-10 | 2022-11-16 | Bright Peak Therapeutics AG | Modified il-2 polypeptides and uses thereof |
| MX2022008771A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Metodos y composiciones de muteinas de il2 sesgadas. |
| AU2021280245A1 (en) * | 2020-05-26 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering a PD-1 inhibitor |
| CN116133676A (zh) | 2020-06-03 | 2023-05-16 | 阿森迪斯药物肿瘤股份有限公司 | Il-2序列及其用途 |
| WO2022098954A1 (en) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Tlr agonist compounds and related cancer immunotherapy methods |
| AU2021376864A1 (en) | 2020-11-10 | 2023-06-29 | Catalym Gmbh | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| DK4267105T3 (da) | 2020-12-28 | 2025-05-19 | Bristol Myers Squibb Co | Antistofsammensætninger og fremgangsmåder til anvendelse deraf |
| MX2023011517A (es) * | 2021-03-29 | 2023-11-28 | Od Therapeutics Ltd | Conjugados de proteina-macromolecula y metodos de uso de los mismos. |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022256538A1 (en) * | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab |
| JP2024524534A (ja) | 2021-07-09 | 2024-07-05 | ブライト ピーク セラピューティクス エージー | 炎症性疾患及び自己免疫疾患の治療のための修飾ｉｌ－２ポリペプチド |
| CA3258064A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| CN101084012A (zh) * | 2004-05-20 | 2007-12-05 | 津莫吉尼蒂克斯公司 | 使用il－21和单克隆抗体疗法治疗癌症的方法 |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CN101242858B (zh) | 2005-06-16 | 2012-12-19 | 尼克塔治疗公司 | 具有可降解键的轭合物以及用于制备这种轭合物的聚合物试剂 |
| BR112013011659A2 (pt) | 2010-11-12 | 2016-08-02 | Endocyte Inc | métodos de tratamento do câncer |
| CN110812488A (zh) * | 2010-11-12 | 2020-02-21 | 尼克塔治疗公司 | Il-2部分与聚合物的缀合物 |
| JP6322413B2 (ja) * | 2011-03-10 | 2018-05-09 | プロヴェクタス ファーマテック，インク． | 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ |
| SMT202100191T1 (it) | 2014-02-21 | 2021-05-07 | Nektar Therapeutics | Agonisti selettivi per il-2rbeta in combinazione con un anticorpo anti.ctla-4 o un anticorpo anti-pd-1 |
-
2015
- 2015-02-20 SM SM20210191T patent/SMT202100191T1/it unknown
- 2015-02-20 SI SI201531552T patent/SI3134123T1/sl unknown
- 2015-02-20 ES ES15721044T patent/ES2872848T3/es active Active
- 2015-02-20 PL PL15721044T patent/PL3134123T3/pl unknown
- 2015-02-20 EP EP20217706.9A patent/EP3834838A1/en not_active Withdrawn
- 2015-02-20 KR KR1020167023162A patent/KR102410090B1/ko active Active
- 2015-02-20 WO PCT/IN2015/000099 patent/WO2015125159A1/en not_active Ceased
- 2015-02-20 DK DK15721044.4T patent/DK3134123T3/da active
- 2015-02-20 IL IL247320A patent/IL247320B/en unknown
- 2015-02-20 EP EP15721044.4A patent/EP3134123B1/en not_active Revoked
- 2015-02-20 CN CN201580009152.0A patent/CN106132438B/zh active Active
- 2015-02-20 AU AU2015220408A patent/AU2015220408B2/en active Active
- 2015-02-20 RS RS20210363A patent/RS61661B1/sr unknown
- 2015-02-20 HU HUE15721044A patent/HUE053982T2/hu unknown
- 2015-02-20 HR HRP20210377TT patent/HRP20210377T1/hr unknown
- 2015-02-20 CA CA2937660A patent/CA2937660A1/en active Pending
- 2015-02-20 JP JP2016570201A patent/JP6963385B2/ja active Active
- 2015-02-20 US US15/120,214 patent/US10010587B2/en active Active
- 2015-02-20 PT PT157210444T patent/PT3134123T/pt unknown
- 2015-02-20 LT LTEP15721044.4T patent/LT3134123T/lt unknown
- 2015-02-20 MX MX2016010870A patent/MX385194B/es unknown
-
2016
- 2016-08-19 MX MX2021009926A patent/MX2021009926A/es unknown
-
2018
- 2018-06-04 US US15/997,487 patent/US10786552B2/en active Active
-
2019
- 2019-02-01 JP JP2019016875A patent/JP2019077723A/ja not_active Withdrawn
-
2020
- 2020-08-04 AU AU2020213296A patent/AU2020213296A1/en not_active Abandoned
- 2020-08-12 US US16/991,936 patent/US20200368321A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018007A patent/JP2021073296A/ja not_active Withdrawn
- 2021-04-07 CY CY20211100297T patent/CY1124226T1/el unknown
-
2022
- 2022-05-25 AU AU2022203550A patent/AU2022203550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506264A5 (enExample) | ||
| Sternberg et al. | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| Ghiringhelli et al. | The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| Wang et al. | Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2017536340A5 (enExample) | ||
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| HK1255039A1 (zh) | 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 | |
| MA41038B1 (fr) | Composés d'aminopyridyloxypyrazole | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2018508483A5 (enExample) | ||
| MY200162A (en) | Anti-gitr antibodies and uses thereof | |
| JP2015532292A5 (enExample) | ||
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| JP2016540042A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2018516911A5 (enExample) | ||
| WO2012177595A9 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| HK1250990A1 (zh) | 凝血因子xi抗体及使用方法 | |
| EP4302784A3 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| WO2011106300A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| WO2015157629A3 (en) | Antibodies, pharmaceutical compositions and uses thereof |